KOLINPHARMA® obtains a patent in the United States of America for Dolatrox® - 10/03/2020
![](/46/pdcnewsitem/08/32/14/Dolatrox.jpg)
Dolatrox® is a composition for the treatment of arthropathies and osteoarthritis, as stated in the patent certificate. This composition was thus recognized as innovative and unique. Dolatrox is the 4th patent that Kolinpharma obtains in the USA.
"Obtaining the fourth patent, in a country like the United States, a worldwide reference in scientific research, is a huge source of pride for us" - comments the president, Rita Paola Petrelli.
![Kolinpharma](https://www.cphi-online.com/c286574th_S-comp286574.jpg)
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Seeking new opportunities: Novel drug approvals of 2024 infographic
In this informative infographic find out about the drugs that have been approved so far in 2024 by the US FDA. Covering a range of fields from infectious diseases to oncology, to drugs for diagnostics this year has seen a diverse range of approvals. We... -
News Alzheimer's drug from Eli Lilly gets recommendation from FDA advisory panel
An advisory panel to the FDA recently analysed the trial for donanemab, the experimental Alzheimer's drug from Eli Lilly, to determine whether they deemed it safe enough to use in patients, even amid concerns over some of the adverse effects seen w... -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance